Loading clinical trials...
Loading clinical trials...
Improvement of Hypodopaminergic Syndrome With Dopaminergic Treatment in Early Parkinson's Disease
The objective of this study is to describe the evolution of hypodopaminergic syndrome in patients with Parkinson's disease.
All patients to be included have been clinically described in the early phase of their disease, before instauration of dopaminergic treatment, in the context of a former study ("Non Motor Aspects in De Novo Parkinson's Disease (Honeymoon) NCT02786667") between june 2012 and june 2016. 3 to 5 years after this study, those patients who started dopaminergic treatment will be evaluated again. The objective of this study, which takes place 3 to 5 year after the initial evaluation, is to measure the evolution of apathy and other symptoms of the hypodopaminergic syndrome. Secondary objectives are the evolution of other parameters including pain, personality and behavior. All parameters measured have been determined of each patient in the Honeymoon study.
Age
33 - 72 years
Sex
ALL
Healthy Volunteers
No
University Hospital of Grenoble
Grenoble, France
Hôpital Neurologique Pierre Wertheimer
Lyon, France
Centre Expert Régional pour la maladie de Parkinson
Poitiers, France
Hôpital de Hautepierre
Strasbourg, France
Start Date
February 23, 2017
Primary Completion Date
March 11, 2020
Completion Date
March 11, 2020
Last Updated
March 29, 2021
90
ACTUAL participants
Starkstein scale of Apathy
OTHER
Lead Sponsor
University Hospital, Grenoble
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT06113640